Nightstar has added a licence for a potential treatment of Stargardt disease to its portfolio.

Microbiosensor will use the funding to advance its handheld infection diagnosis tool through critical development and clinical testing.

The pharmaceutical firm has joined forces with Centre for Drug and Research Development to fund new life science therapies.

Taikang Insurance’s Industry Development Fund has backed a series B round for cancer therapy developer EOC, which was spun off from Eddingpharm.

The Public University of Navarre spinout will use the funds to prepare clinical trials of its biomarker-based asthma diagnosis device.

Softbank has backed the online health portal in a $7m series B round that will fund expansion into new markets in Southeast Asia.

The Germany-based, Ammann and Staidson-backed inflammatory disease therapy developer has floated in an initial public offering in the US.

KingMed Diagnostics and WuXi AppTech have contributed to a $28m round that will fund the precision medicine developer's cancer DNA research.